Pharma and Biotech Daily: Trump's Tariff Threats and Pharma's Response

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump has opened a national security probe on pharmaceutical imports, potentially leading to tariffs on these products. Johnson & Johnson reported strong earnings in Q1 thanks to certain drugs, while a phase III trial for BMS' Camzyos did not show new benefits. J&J CEO Joaquin Duato called for tax changes instead of tariffs to encourage drug manufacturing in the U.S. Merck is exploring oral peptide delivery through a new deal, while Boehringer Ingelheim is expanding its portfolio in the inflammation and immunology space. In response to Trump's tariff threats, J&J and other pharma companies are investing in U.S. manufacturing. Thank you for listening to Pharma and Biotech daily.